Actively Recruiting

Age: 18Years +
All Genders
NCT03897582

Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study

Led by Centre Hospitalier de Valenciennes · Updated on 2024-02-02

65

Participants Needed

1

Research Sites

379 weeks

Total Duration

On this page

Sponsors

C

Centre Hospitalier de Valenciennes

Lead Sponsor

C

Centre Hospitalier de Lens

Collaborating Sponsor

AI-Summary

What this Trial Is About

Pneumonia are the most frequent infections in ICU. Little is known about beta-lactam doses necessary for this infection for patients treated with continuous veino-veinous hemodialysis. The pharmacokinetic variability expose to over and underdosage leading to toxicity or therapeutic failure. The aim of this study is to define if beta-lactams doses used in pneumonia for patients with acute kidney injury treated with our hemodialysis conditions lead to beta-lactam therapeutic plasma levels.

CONDITIONS

Official Title

Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 18 years or older
  • Receiving intravenous beta-lactam antibiotics: amoxicillin, amoxicillin-clavulanic acid, piperacillin-tazobactam, cefotaxime, ceftazidime, cefepime, meropenem, or imipenem
  • Have acute kidney injury (AKI) defined by one or more of: increase in creatinine  0.3 mg/dl within 48 hours, increase in creatinine  1.5 times baseline within 7 days, or urine output < 0.5 ml/kg/h for 6 hours
  • Treated with Multifiltrate Ci-Ca CVVHD 1000 kit with dialysis dose of 25 ml/kg/h
  • Hospitalized in ICU
  • Have a catheter to facilitate blood sample collection
  • Diagnosed with pneumonia defined by chest X-ray showing opacities or infiltrates, plus fever (> 386C) or low temperature (< 366C), plus respiratory symptoms such as new or worsening cough, purulent sputum, or increased oxygen needs
  • Treated within 24 hours by citrate hemodialysis and beta-lactam doses and administration matching the study protocol
  • No objection from patient or legally authorized representative
Not Eligible

You will not qualify if you...

  • Younger than 18 years
  • Receiving extracorporeal membrane oxygenation (ECMO)
  • Diagnosis of cystic fibrosis
  • Burn injury
  • Pregnant
  • Any rapidly progressing disease or life-threatening illness
  • Objection from patient or legally authorized representative
  • No social security coverage
  • Antibiotic treatment interrupted before sample collection
  • Currently imprisoned

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Centre Hospitalier de Valenciennes

Valenciennes, Nord, France, 59300

Actively Recruiting

Loading map...

Research Team

F

Fabien Lambiotte, MD

CONTACT

J

Justine Lemtiri, Pharm D

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here